Skip to content
AgingNexus
☰ Menu

Evidence brief · intervention

Metformin

Synthesized from 10 indexed sources · 2026-06-04 MST · preview (no AI key)
Preview synthesis (deterministic, no AI key configured). Set a provider key to generate the full brief.

Synthesis (preview — no live AI key for the active provider):

Across the retrieved literature, senescent-cell burden and chronic inflammation recur as central, interacting drivers, with intervention studies reporting functional gains in model organisms. Key works: [1][2][3][4][5].

Set the active provider's API key to generate full model-written analysis.

Sources

  1. [1] Metformin improves healthspan and lifespan in mice
  2. [2] Metformin Induces a Dietary Restriction–Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1
  3. [3] The Therapeutic Potential of Metformin in Neurodegenerative Diseases
  4. [4] A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan
  5. [5] Metformin: A Therapeutic Opportunity in Breast Cancer
  6. [6] Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing
  7. [7] Epigenetic effects of metformin: From molecular mechanisms to clinical implications
  8. [8] Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms
  9. [9] [The effect of geroprotectors on life expectancy: Mechanisms of action and clinical potential.]
  10. [10] Plasma Proteome Profiling of Centenarian Across Switzerland Reveals Key Youth-Associated Proteins.
All Metformin works → Intervention dossier →